BrainStorm Cell Therapeutics Announces Second Quarter 2022 F

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

Related Keywords

California , United States , Stanford School , Massachusetts , Ukraine , American , John Mullaly , Kim Thacker , Netta Blondheim Shraga , Chaim Lebovits , Antal Pearl Lendner , Jonathan Katz , Ralph Kern , Sidney Spector , Lisa Guiterman , James Berry , Drug Administration For Nurown , Stanford School Of Medicine , California Pacific Medical Center , Research Development , Preclinical Research , Nasdaq , International Society For Extracellular Vesicles , Neurology Department , California Institute For Regenerative Medicine , Brainstorm Cell Therapeutics Inc , European Network For The Cure , Lifesci Advisors , Drug Administration , International Society , Drug Development Summit , Prnewswire Brainstorm Cell Therapeutics Inc , Consortium Of Multiple Sclerosis Centers , National Ms Society , European Medicines Agency , American Academy Of Neurology Congress , Biologics License Application , Storm Cell Therapeutics , Cell Therapeutics , Chief Executive , Second Quarter , Forbes Norris , California Pacific Medical , Neurology Congress , Massachusetts General Hospital Multidisciplinary , Motor Neuron , Development Summit , Chief Medical Officer , Comprehensive Longitudinal Investigation , Multiple Sclerosis , Multiple Sclerosis Centers , Christopher Lock , Clinical Associate Professor , Neurological Studies , Senior Vice President , Medical Affairs , Global Strategy , Brainstorm Cell , Extracellular Vesicles , Haggai Kaspi , Preclinical Research Manager , Gene Therapy , Clinical Innovation , Chief Legal , Second Quarter Ended June , Access Code , Orphan Drug , California Institute , Regenerative Medicine , Brainstorm Cell Therapeutics , Sci Advisors , Term Assets , Term Liabilities ,